AT249263B - Röntgenkontrastmittel - Google Patents
RöntgenkontrastmittelInfo
- Publication number
- AT249263B AT249263B AT922963A AT922963A AT249263B AT 249263 B AT249263 B AT 249263B AT 922963 A AT922963 A AT 922963A AT 922963 A AT922963 A AT 922963A AT 249263 B AT249263 B AT 249263B
- Authority
- AT
- Austria
- Prior art keywords
- sep
- triiodo
- acetylamino
- benzoic acid
- solution
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims description 32
- 229940039231 contrast media Drugs 0.000 title description 16
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 18
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 7
- -1 amine salts Chemical class 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000126 substance Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000007487 urography Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 159000000000 sodium salts Chemical class 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000002583 angiography Methods 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000002585 cerebral angiography Methods 0.000 description 4
- 230000000254 damaging effect Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- ULBJILHSWMGASA-UHFFFAOYSA-N 1-(2-methoxy-4-nitrophenyl)pyrrolidine Chemical compound COC1=CC([N+]([O-])=O)=CC=C1N1CCCC1 ULBJILHSWMGASA-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- VWSLLSXLURJCDF-UHFFFAOYSA-N 2-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000012336 iodinating agent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1378862A CH414063A (de) | 1962-11-23 | 1962-11-23 | Röntgenkontrastmittel |
| CH985763A CH435563A (de) | 1962-11-23 | 1963-08-09 | Röntgenkontrastmittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT249263B true AT249263B (de) | 1966-09-12 |
Family
ID=25705437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT922963A AT249263B (de) | 1962-11-23 | 1963-11-18 | Röntgenkontrastmittel |
Country Status (12)
| Country | Link |
|---|---|
| AT (1) | AT249263B (forum.php) |
| BE (1) | BE640222A (forum.php) |
| BR (1) | BR6354529D0 (forum.php) |
| CH (1) | CH435563A (forum.php) |
| DE (1) | DE1273747B (forum.php) |
| DK (1) | DK107965C (forum.php) |
| ES (1) | ES293218A1 (forum.php) |
| FI (1) | FI42984C (forum.php) |
| FR (1) | FR3449M (forum.php) |
| GB (1) | GB1002344A (forum.php) |
| NL (2) | NL300867A (forum.php) |
| SE (2) | SE316870B (forum.php) |
-
1963
- 1963-08-09 CH CH985763A patent/CH435563A/de unknown
- 1963-09-24 DE DEE25581A patent/DE1273747B/de active Pending
- 1963-10-03 GB GB39021/63A patent/GB1002344A/en not_active Expired
- 1963-11-05 ES ES293218A patent/ES293218A1/es not_active Expired
- 1963-11-13 BR BR154529/63A patent/BR6354529D0/pt unknown
- 1963-11-18 AT AT922963A patent/AT249263B/de active
- 1963-11-20 BE BE640222A patent/BE640222A/xx unknown
- 1963-11-21 FR FR954579A patent/FR3449M/fr not_active Expired
- 1963-11-21 SE SE12875/63A patent/SE316870B/xx unknown
- 1963-11-22 DK DK548263AA patent/DK107965C/da active
- 1963-11-22 NL NL300867D patent/NL300867A/xx unknown
- 1963-11-22 FI FI632280A patent/FI42984C/fi active
- 1963-11-22 NL NL300867A patent/NL130868C/xx active
-
1966
- 1966-08-08 SE SE10725/66A patent/SE327193B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH435563A (de) | 1967-05-15 |
| FR3449M (fr) | 1965-07-26 |
| SE316870B (forum.php) | 1969-11-03 |
| FI42984C (fi) | 1970-12-10 |
| DE1273747B (de) | 1968-07-25 |
| FI42984B (forum.php) | 1970-09-02 |
| DK107965C (da) | 1967-07-24 |
| NL130868C (forum.php) | 1971-03-15 |
| BR6354529D0 (pt) | 1973-02-22 |
| BE640222A (forum.php) | 1964-05-20 |
| ES293218A1 (es) | 1964-01-16 |
| SE327193B (forum.php) | 1970-08-17 |
| NL300867A (forum.php) | 1965-09-27 |
| GB1002344A (en) | 1965-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH414063A (de) | Röntgenkontrastmittel | |
| EP0602585B1 (de) | Dialyselösung für die Peritonealdialyse | |
| DE3316703A1 (de) | Orales kontrastmittel fuer die kernspintomographie und dessen herstellung | |
| DE3002004A1 (de) | Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung | |
| EP0426610B1 (de) | Nichtionisches Röntgenkontrastmittel mit hohem Jodgehalt | |
| DD295992A5 (de) | Kontrastmittel | |
| DE69003174T2 (de) | Etoposid-Präparate. | |
| DE2819319C2 (de) | Träger für ↑9↑↑9↑↑m↑ TC markierte diagnostische Mittel und diesen enthaltendes radioaktives diagnostisches Mittel | |
| AT249263B (de) | Röntgenkontrastmittel | |
| DE1643493A1 (de) | Verfahren zur Sichtbarmachung von Koerperhoehlungen mit Roentgenstrahlen und Praeparat zur Durchfuehrung dieses Verfahrens | |
| CH615344A5 (en) | X-ray contrast medium and process for its preparation | |
| CH497898A (de) | Verfahren zur Herstellung wässriger Lösungen von praktisch wasserunlöslichen Phenoxyessigsäureamiden | |
| CH438584A (de) | Röntgenkontrastmittel | |
| DE68903597T2 (de) | Weichkapselzubereitung von natriumpicosulfat. | |
| AT218175B (de) | Röntgenkontrastmittel zur Sichtbarmachung der Gallenwege | |
| DE1937211C3 (de) | 4,7,10,13-Telraoxahexadecan-i ,16dioyl-bis-(3-carboxy-2,4,6-trijod-anilid) und dessen Salze, Verfahren zur Herstellung dieser Verbindungen sowie diese Verbindungen enthaltende Röntgenkontrastmittel | |
| DE749431C (de) | Roentgenkontrastmittel | |
| EP0128578A1 (de) | Ethanolische Kontrastmittelsuspensionen | |
| EP0108248B2 (de) | Lösungsvermittlerfreie, wässrige Nitroglycerinlösung | |
| AT289769B (de) | Verfahren zur Herstellung des neuen 4,7,10,13-Tetraoxahexadecan-1,16-disäure-bis-(3'carboxy-2',4',6'-trijodanilids) und dessen Salze | |
| DE919908C (de) | Roentgenkontrastmittel zur Bronchographie und Hysterosalpingographie | |
| DE1617743A1 (de) | Roentgenkontrastmittel | |
| DE2028595A1 (de) | Verbessertes Röntgenkontrastmittel | |
| DE646116C (de) | Kontrastmittel zur roentgenologischen Sichtbarmachung von Hohlsystemen des Koerpers | |
| AT286494B (de) | Röntgenkontrastmittel |